Abstract:In view of the high recurrence rate of Graves' disease (GD) treated with antithyroid drugs (ATD), it is very important to find suitable markers with prognostic value for ATD treatment of GD. Recently, nucleic acid markers, such as single nucleotide polymorphism (SNP), microRNAs and metabolomics parameters, have been gradually used in the diagnosis and prognosis assessment of GD. Among them, SNP is of great value in predicting the remission or recurrence of GD treated with ATD. Clarifying the relationship between the above small molecules substances and the recurrence of GD after ATD treatment is helpful to find out the new factors affecting the prognosis of GD, and provide more precise guidance for treatment decision-making. This paper reviews the research on the value of new molecular markers in the prediction of GD recurrence risk and the future research direction.